Neumora Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 |
|---|---|---|---|---|
| Operating income | -$241.2M | -$263.5M | -$252.1M | -$135.9M |
| Operating expenses | $241.2M | $263.5M | $252.1M | $135.9M |
| Cash from operations | -$206.4M | -$182.9M | -$163.3M | -$114.9M |
| Capital expenditure | — | — | $117,000 | $511,000 |
| Free cash flow | — | — | -$163.4M | -$115.4M |
| Impairments | $595,000 | $0 | — | — |
| Total assets | $191.0M | $317.0M | $496.2M | $426.2M |
| Total liabilities | $87.2M | $29.9M | $27.1M | $29.4M |
| Total debt | $60.2M | — | — | — |
Shares outstanding 185.3M · Free float 48.0%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.